piperacillin has been researched along with ertapenem in 99 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 61 (61.62) | 29.6817 |
2010's | 37 (37.37) | 24.3611 |
2020's | 1 (1.01) | 2.80 |
Authors | Studies |
---|---|
Cornaglia, G; Koncan, R; Mazzariol, A; Roelofsen, E; Voss, A | 1 |
Correa, A; Kattan, JN; Lolans, K; Lopez, JA; Quinn, JP; Villegas, MV | 1 |
Bille, J; Lartigue, MF; Nordmann, P; Poirel, L; Wenger, A; Zinsius, C | 1 |
Carmeli, Y; Chmelnitsky, I; Leavitt, A; Navon-Venezia, S; Schwaber, MJ | 1 |
Calvet, L; Devine, R; Dubreuil, L; Jean-Pierre, H; Jumas-Bilak, E; Marchandin, H; Mercier, G; Morio, F | 1 |
Cuzon, G; Demachy, MC; Naas, T; Nordmann, P | 1 |
Cuzon, G; Lartigue, MF; Naas, T; Nordmann, P; Quinn, JP; Villegas, MV | 1 |
Baudry, PJ; DeCorby, M; Hoban, DJ; Mataseje, L; Mulvey, MR; Nichol, K; Zhanel, GG | 1 |
Cai, JC; Chen, GX; Zhang, R; Zhou, HW | 1 |
Castanheira, M; Deshpande, LM; Martin, CA; Morita, K; Ribes, JA; Sader, HS | 1 |
Bethel, CR; Bonomo, RA; Carias, LL; Endimiani, A; Fox, WR; Hall, GS; Hujer, AM; Hujer, KM; Hutton, RA; Jacobs, MR; Jenkins, SG; Paterson, DL; Perez, F; Rice, LB; Tenover, FC | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Badur, S; Cagatay, AA; Carrër, A; Eraksoy, H; Nordmann, P; Poirel, L | 1 |
Carmeli, Y; Chmelnitsky, I; Navon-Venezia, S; Strahilevitz, J | 1 |
Castanheira, M; Samuelsen, Ø; Spencer, J; Walsh, TR | 1 |
Hsueh, PR; Huang, YT; Liao, CH; Lin, HY; Liu, CY; Yen, LC | 1 |
Bogaerts, P; Cuzon, G; Glupczynski, Y; Huang, TD; Naas, T; Nordmann, P | 1 |
Brown, NP; Pillar, CM; Sahm, DF; Shah, D; Torres, MK | 1 |
Jacobus, NV; McDermott, LA; Snydman, DR | 1 |
Bennett, JW; Herrera, ML; Jorgensen, JH; Lewis, JS; Wickes, BW | 1 |
Baptista, BC; Correia, JD; da Fonseca, JD; Martínez-Martínez, L; Pomba, C | 1 |
Bell, JM; Castanheira, M; Deshpande, LM; Jones, RN; Mendes, RE; Turnidge, JD | 1 |
Goering, RV; Hanson, ND; Kurpiel, PM; Palepou, MF; Wolter, DJ; Woodford, N | 1 |
Bell, JM; Castanheira, M; Jones, RN; Mathai, D; Turnidge, JD | 1 |
Adams-Haduch, JM; Bonomo, RA; Doi, Y; Endimiani, A; O'Keefe, A; Paterson, DL; Sidjabat, HE | 1 |
Badal, RE; Bouchillon, SK; Hawser, SP; Hoban, DJ; Hsueh, PR; Paterson, DL | 1 |
Giakkoupi, P; Miriagou, V; Papagiannitsis, CC; Pappa, O; Polemis, M; Tzouvelekis, LS; Vatopoulos, AC; Zioga, A | 1 |
Bauernfeind, A; Keuleyan, E; Markova, B; Markovska, R; Queenan, AM; Schneider, I | 1 |
Du, X; Ji, S; Jiang, Y; Li, L; Shen, P; Wei, Z; Yu, Y | 1 |
Carattoli, A; Ellington, MJ; Karisik, E; Livermore, DM; Underwood, A; Woodford, N | 1 |
Cho, HS; Giske, CG; Lee, K; Sundman, K; Toleman, MA; Walsh, TR; Yong, D | 1 |
Girlich, D; Nordmann, P; Poirel, L | 3 |
Aggoune-Khinache, N; Bonnet, R; Delmas, J; Naim, M; Robin, F | 1 |
Fortineau, N; Nordmann, P; Poirel, L; Rodriguez-Martinez, JM | 1 |
Akan, OA; Carrër, A; Cuzon, G; Feriha, C; Honderlick, P; Matar, G; Nordmann, P; Poirel, L; Yilmaz, M | 1 |
Carmeli, Y; Chmelnitsky, I; Goren, MG; Navon-Venezia, S | 1 |
Carmeli, Y; Chmelnitsky, I; Goren, MG; Leavitt, A; Navon-Venezia, S; Ofek, I | 1 |
Bonomo, RA; Distler, AM; Endimiani, A; Hornick, JM; Hujer, AM; Hujer, KM; Papp-Wallace, KM; Taracila, M | 1 |
Badal, RE; Bouchillon, SK; DiPersio, J; Hawser, SP; Hoban, DJ; Labombardi, VJ | 1 |
Bini, L; Bonomo, RA; Borgianni, L; Docquier, JD; Frère, JM; Matagne, A; Rossolini, GM; Vandenameele, J | 1 |
Cars, O; Löwdin, E; Melhus, A; Tängdén, T | 1 |
Jiang, Y; Shen, P; Wei, Z; Yu, D; Yu, Y; Zhou, Z | 1 |
Carattoli, A; García-Fernández, A; Giordano, A; Mancini, C; Miriagou, V; Papagiannitsis, CC; Venditti, M | 1 |
Lagrutta, E; Nordmann, P; Pham, J; Poirel, L; Taylor, P | 1 |
Chien, CC; Lee, CH; Li, CC; Liu, JW; Su, LH; Tang, YF | 1 |
Borgianni, L; Docquier, JD; Hanson, ND; Prandi, S; Rossolini, GM; Salden, L; Santella, G | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Ceesay, TP; Gesser, R; Graham, DR; Holtom, P; Lucasti, C; Malafaia, O; McAdams, A; Nichols, RL; Perez, NQ; Woods, GL | 1 |
Citron, DM; Gesser, RM; Goldstein, EJ; Merriam, CV; Tyrrell, KL; Warren, Y | 1 |
Friedland, I; Majumdar, A; Mixson, LA; Motyl, M; Woods, GL | 1 |
Carides, A; Choe, KA; Christou, NV; Dellinger, EP; Fernandez, A; Malafaia, O; Rotstein, OD; Satishchandran, V; Solomkin, JS; Tellado, JM; Teppler, H; Yellin, AE | 1 |
Gesser, R; McCarroll, K; Tellado, J; Teppler, H; Woods, GL | 1 |
Gesser, RM; McCarroll, K; Teppler, H; Woods, GL | 2 |
Zaĭtsev, AA | 1 |
Adeyi, B; Angel-Muller, E; Hague, C; Higareda, I; Ismail, M; Roy, S; Teppler, H; Woods, GL | 1 |
Gesser, RM; McCarroll, KA; Woods, GL | 2 |
Meibohm, AR; Teppler, H; Woods, GL | 1 |
Gesser, RM; Graham, DR; Meibohm, AR; Roy, S; Solomkin, J; Teppler, H; Woods, GL | 1 |
Friedland, IR; Gesser, RM; Herman, G; Isaacs, R; Meibohm, A; Mistry, G; Teppler, H; Woods, GL | 1 |
Baysallar, M; Doğanci, L; Kiliç, A; Küçükkaraaslan, A; Senses, Z | 1 |
Chan, CY; Dinubile, MJ; Friedland, I; Giezek, H; Motyl, MR; Quinn, JP; Shivaprakash, M; Weinstein, RA | 1 |
Abramson, MA; Chow, JW; DiNubile, MJ; Motyl, MR; Polis, A; Satishchandran, V; Teppler, H | 1 |
Abramson, MA; Armstrong, DG; Citron, DM; Lipsky, BA; Morgenstern, DE; Tice, AD | 1 |
Asperger, W; Chan, CY; Dela Pena, AS; DiNubile, MJ; Giezek, H; Kafka, R; Köckerling, F; Raz, R; Shivaprakash, M; Vrijens, F; Warren, B | 1 |
Donskey, CJ; Pultz, NJ; Stiefel, U | 1 |
Borbone, S; Cascone, C; Mezzatesta, ML; Santagati, M; Stefani, S | 1 |
Broide, E; Raveh, D; Rudensky, B; Yinnon, AM | 1 |
Abramson, MA; Jensen, EH; Namias, N; Solomkin, JS; Tomassini, JE | 1 |
Abramson, MA; Armstrong, DG; Lipsky, BA; Polis, AB; Sheehan, P; Tice, AD | 1 |
Abramson, MA; Hoey, CT; Lipsky, BA; Tice, AD; Turpin, RS; Wu, J | 1 |
Apolônio, ACM; Coutinho, SC; Diniz, CG; Farias, LM; Geralda de Sousa-Gaia, L; Nicoli, JR; Roque de Carvalho, MA; Valéria Dos Santos, K | 1 |
Apolônio, ACM; Carvalho, MAR; Coutinho, SC; Diniz, CG; Farias, LM; Martins, WA; Nicoli, JR; Santos, KVD | 1 |
Chang, KT; Ledesma, KR; Quinn, JP; Tam, VH; Wang, TY | 1 |
Carmeli, Y; Jansen, JP; Kumar, R | 1 |
An, MM; Chen, ML; Jiang, YY; Liu, P; Shen, H; Wang, R; Zhang, JD; Zou, Z | 1 |
Amancio Martins, W; Bahia, JL; Cara, DC; Coutinho, SC; DE Macedo Farias, L; Galuppo Diniz, C; Lopes DE Andrade, JP; Morais Apolonio, AC; Nicoli, JR; Roque DE Carvalho, MA; Valéria Dos Santos, K | 1 |
Hawser, SP | 1 |
Hille, DA; Namias, N; Zakrison, TL | 1 |
Couet, W; Grégoire, N; Marliat, M; Mimoz, O; Nordmann, P; Poirel, L | 1 |
Chen, YH; Chen, YS; Chuang, YC; Ho, CM; Hsueh, PR; Huang, CC; Ko, WC; Lee, YL; Liu, CE; Liu, YC; Liu, YM; Lu, PL; Ni, Y; Tang, HJ; Toh, HS; Wang, JH; Xu, Y; Yu, KW | 1 |
Bandettini, R; Buffa, P; Castagnola, E; Caviglia, I; Ciucci, A; Ginocchio, F; Guida, E; Haupt, R; Loy, A; Masa, DL; Mattioli, G; Perotti, M; Pini Prato, A | 1 |
Cavanillas, R; Grau, S; Lozano, V; Nocea, G; Valladares, A; Xie, Y | 1 |
Badal, RE; Cao, B; Chen, S; Chu, Y; Duan, Q; Feng, X; Gui, B; Hu, B; Hu, Z; Huang, W; Kong, H; Liao, K; Luo, Y; Ni, Y; Shao, H; Su, J; Sun, Z; Wang, Y; Wu, A; Xu, Y; Yang, Q; Yu, Y; Zhang, H; Zhang, S | 1 |
Hung, YP; Ko, WC; Lee, JC; Li, CW; Li, MC; Lin, HJ; Liu, HC; Wu, YH | 1 |
Gan, WJ; Mu, SM; Ran, XW; Shen, JF; Wang, J; Xian, Y; Xu, ZR; Yan, XD; Yuan, GY; Zhang, BS | 1 |
Banerjee, R; Boyce, TG; Cunningham, SA; Hasassri, ME; Jeraldo, PR; Kaye, KS; Norgan, AP; Patel, R; Pogue, JM; Weissman, SJ | 1 |
Dixon, N; Fowler, RC; Geyer, CN; Hanson, ND; Harrison, L; Horiyama, T; Ishii, Y; Moland, ES; Thomson, K; Yoshizumi, A | 1 |
Carroll, K; Romagnoli, M; Simner, PJ; Wang, F; Workneh, M | 1 |
Hackel, MA; Hoban, DJ; Karlowsky, JA; Lob, SH; Sahm, DF | 1 |
Dizbay, M; Karaşahin, EF; Karaşahin, Ö; Özger, HS | 1 |
Kim, JH; Kim, MJ; Sohn, JW; Yang, KS; Yoon, YK | 1 |
Kim, HS; Kim, HY; Kim, YK; Lee, J; Lee, JA; Lee, SS; Seo, YB; Song, W; Uh, Y | 1 |
Allerberger, F; Jesumirhewe, C; Lepuschitz, S; Ruppitsch, W; Springer, B | 1 |
Logan, J; Mellor, TE; Mitchell, N | 1 |
Academia, EC; Jenrette, JE; McLaughlin, JM; Mueller, SW | 1 |
4 review(s) available for piperacillin and ertapenem
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Safety and tolerability of ertapenem.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; beta-Lactams; Ceftriaxone; Clinical Trials as Topic; Community-Acquired Infections; Ertapenem; Female; Humans; Lactams; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Randomized Controlled Trials as Topic | 2004 |
Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Ertapenem; Humans; Penicillanic Acid; Piperacillin; Randomized Controlled Trials as Topic; Tazobactam; Treatment Outcome | 2009 |
Lemierre's syndrome variant of the gut.
Topics: Abdominal Pain; Anti-Bacterial Agents; Anticoagulants; beta-Lactams; Endoscopy, Gastrointestinal; Ertapenem; Fever; Fusobacterium Infections; Fusobacterium necrophorum; Heparin; Humans; Lemierre Syndrome; Male; Penicillanic Acid; Phlebitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Portal Vein; Treatment Outcome | 2017 |
19 trial(s) available for piperacillin and ertapenem
Article | Year |
---|---|
Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Ertapenem; Female; Humans; Lactams; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Penicillins; Piperacillin; Prospective Studies; Pseudomonas aeruginosa; Skin Diseases; Staphylococcus aureus; Tazobactam; Treatment Outcome | 2002 |
General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; beta-Lactams; Double-Blind Method; Enzyme Inhibitors; Ertapenem; Humans; Lactams; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Skin Diseases, Bacterial; Tazobactam | 2002 |
Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial.
Topics: Abdominal Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Digestive System Surgical Procedures; Double-Blind Method; Drug Therapy, Combination; Ertapenem; Female; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Hospitalization; Humans; Lactams; Male; Middle Aged; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Research Design; Treatment Outcome | 2003 |
Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections.
Topics: Abdomen; Adult; Aged; Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; beta-Lactams; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ertapenem; Female; Humans; Lactams; Male; Middle Aged; Pelvic Infection; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Skin Diseases, Bacterial; Surgical Wound Infection | 2002 |
Surgical infections with enterococcus: outcome in patients treated with ertapenem versus piperacillin-tazobactam.
Topics: Abdomen; Adolescent; Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Enterococcus; Ertapenem; Female; Gram-Positive Bacterial Infections; Humans; Lactams; Male; Middle Aged; Pelvic Infection; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Skin Diseases, Bacterial; Surgical Wound Infection; Treatment Outcome | 2002 |
Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data.
Topics: Adult; Aged; beta-Lactams; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Enterobacteriaceae Infections; Ertapenem; Escherichia coli Infections; Humans; Lactams; Middle Aged; Multicenter Studies as Topic; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome; Urinary Tract Infections | 2003 |
[Carbapenem antibiotic ertapenem in the treatment of extrahospital intraabdominal infections].
Topics: Abdominal Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Double-Blind Method; Ertapenem; Female; Humans; Lactams; Male; Middle Aged; Penicillanic Acid; Peritonitis; Piperacillin; Prospective Studies; Tazobactam; Treatment Outcome | 2003 |
Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study.
Topics: Acute Disease; Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ertapenem; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lactams; Middle Aged; Pelvic Infection; Penicillanic Acid; Piperacillin; Probability; Prospective Studies; Risk Assessment; Severity of Illness Index; Tazobactam; Treatment Outcome | 2003 |
Evaluation of outpatient treatment with ertapenem in a double blind controlled clinical trial of complicated skin/skin structure infections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Chi-Square Distribution; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Ertapenem; Female; Humans; Infusions, Intravenous; Lactams; Logistic Models; Male; Middle Aged; Penicillanic Acid; Piperacillin; Prospective Studies; Skin Diseases; Statistics, Nonparametric; Tazobactam; Treatment Outcome | 2004 |
Management of complicated appendicitis and comparison of outcome with other primary sites of intra-abdominal infection: results of a trial comparing ertapenem and piperacillin-tazobactam.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Appendicitis; Bacterial Infections; beta-Lactams; Colonic Diseases; Demography; Double-Blind Method; Ertapenem; Female; Humans; Lactams; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Risk Factors; Severity of Illness Index | 2004 |
Treatment of polymicrobial infections: post hoc analysis of three trials comparing ertapenem and piperacillin-tazobactam.
Topics: Abdomen; Adolescent; Adult; Anti-Bacterial Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; beta-Lactams; Double-Blind Method; Ertapenem; Female; Humans; Lactams; Male; Pelvic Infection; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Skin Diseases, Bacterial; Treatment Outcome | 2004 |
Efficacy of ertapenem against methicillin-susceptible Staphylococcus aureus in complicated skin/skin structure infections: results of a double-blind clinical trial versus piperacillin-tazobactam.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Double-Blind Method; Ertapenem; Female; Humans; Lactams; Male; Methicillin Resistance; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Skin Diseases, Bacterial; Staphylococcal Infections; Staphylococcus aureus | 2004 |
Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Carrier State; Ceftriaxone; Digestive System Surgical Procedures; Drug Resistance, Bacterial; Drug Therapy, Combination; Ertapenem; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Intestines; Lactams; Male; Metronidazole; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2005 |
Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections.
Topics: Abdominal Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Double-Blind Method; Drug Resistance, Bacterial; Drug Therapy, Combination; Enterobacteriaceae; Ertapenem; Female; Humans; Lactams; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Rectum; Treatment Outcome | 2005 |
Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Diabetic Foot; Double-Blind Method; Drug Administration Schedule; Ertapenem; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Severity of Illness Index; Treatment Outcome | 2005 |
Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention.
Topics: Abdomen; Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Anti-Bacterial Agents; Bacterial Infections; Bacteroides fragilis; Bacteroides Infections; beta-Lactams; Diarrhea; Ertapenem; Escherichia coli Infections; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Treatment Outcome | 2006 |
Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults.
Topics: Abdominal Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; APACHE; Bacterial Infections; Bacteroides; beta-Lactams; Double-Blind Method; Ertapenem; Escherichia coli; Female; Humans; Male; Middle Aged; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2007 |
Ertapenem versus piperacillin/tazobactam for diabetic foot infections in China: a Phase 3, multicentre, randomized, double-blind, active-controlled, non-inferiority trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; beta-Lactamase Inhibitors; beta-Lactams; China; Diabetic Foot; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Ertapenem; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Treatment Outcome; Young Adult | 2016 |
Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cefepime; Cephalosporins; Cross Infection; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Genotype; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Republic of Korea; Tazobactam; Urinary Tract Infections | 2017 |
76 other study(ies) available for piperacillin and ertapenem
Article | Year |
---|---|
Detection of a new SHV-type extended-spectrum beta-lactamase, SHV-31, in a Klebsiella pneumoniae strain causing a large nosocomial outbreak in The Netherlands.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cross Infection; Disease Outbreaks; Drug Resistance, Multiple, Bacterial; Humans; Intensive Care Units; Isoelectric Focusing; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Sequence Data; Netherlands; Plasmids | 2007 |
First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
Topics: beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Hydrolysis; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2007 |
Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland.
Topics: Anti-Bacterial Agents; beta-Lactamases; Community-Acquired Infections; Enterobacteriaceae; Enterobacteriaceae Infections; Escherichia coli; Hospitals, University; Humans; Microbial Sensitivity Tests; Molecular Epidemiology; Polymerase Chain Reaction; Prevalence; Switzerland | 2007 |
Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Hospitals; Humans; Israel; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Epidemiology | 2007 |
Antimicrobial susceptibilities and clinical sources of Dialister species.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Species Specificity; Veillonellaceae | 2007 |
Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece.
Topics: Adult; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Female; Greece; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Plasmids | 2008 |
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
Topics: Base Sequence; beta-Lactamases; beta-Lactams; Cloning, Molecular; Colombia; DNA Transposable Elements; Greece; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA; United States | 2008 |
Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.
Topics: Bacterial Proteins; beta-Lactamases; Canada; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Gentamicins; Humans; Intensive Care Units; Microbial Sensitivity Tests | 2008 |
Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; China; Conjugation, Genetic; Electrophoresis, Gel, Pulsed-Field; Escherichia coli; Hospitals, University; Humans; Hydrolysis; Intensive Care Units; Klebsiella pneumoniae; Microbial Sensitivity Tests; Plasmids; Polymerase Chain Reaction; Serratia marcescens | 2008 |
IMP-15-producing Pseudomonas aeruginosa strain isolated in a U.S. medical center: a recent arrival from Mexico.
Topics: Adult; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Hospitals; Humans; Imipenem; Kentucky; Male; Mexico; Pseudomonas aeruginosa; United States | 2008 |
Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
Topics: Aged; Bacterial Proteins; Base Sequence; beta-Lactamases; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Genes, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Molecular Epidemiology; Plasmids; Quinolones; United States | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
Topics: Bacterial Proteins; beta-Lactamases; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Models, Genetic; Turkey | 2008 |
Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
Topics: Anti-Infective Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Ciprofloxacin; Drug Resistance, Bacterial; Enterobacter cloacae; Genes, Bacterial; Microbial Sensitivity Tests; Plasmids; Quinolones | 2008 |
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
Topics: Acremonium; Bacterial Proteins; beta-Lactamases; Catalysis; Catalytic Domain; Cefepime; Ceftazidime; Cephalosporins; Kinetics; Models, Molecular; Mutation; Penicillinase; Protein Structure, Tertiary; Recombinant Proteins; Structure-Activity Relationship; Substrate Specificity | 2008 |
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacteroides fragilis; Bacteroides Infections; Blood; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Taiwan | 2008 |
Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
Topics: Adult; Anti-Bacterial Agents; Belgium; beta-Lactamases; beta-Lactams; Carbapenems; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Plasmids | 2008 |
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; United States | 2008 |
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacteroides fragilis; Carbapenems; Doripenem; Drug Resistance, Bacterial; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests | 2008 |
KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient.
Topics: Anti-Bacterial Agents; beta-Lactamases; Enterobacter cloacae; Female; Humans; Liver Transplantation; Microbial Sensitivity Tests; Middle Aged; Pseudomonas putida; RNA, Ribosomal, 16S | 2009 |
Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.
Topics: Animals; Anti-Bacterial Agents; Dogs; Drug Resistance, Bacterial; Escherichia coli; Genes, Bacterial; Humans; Plasmids; Virulence | 2009 |
Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program.
Topics: Acinetobacter; Anti-Bacterial Agents; beta-Lactamases; Drug Resistance, Bacterial; Molecular Sequence Data; Plasmids; Population Surveillance; Reverse Transcriptase Polymerase Chain Reaction; Transcription, Genetic | 2009 |
Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Bacteremia; beta-Lactamase Inhibitors; beta-Lactamases; Clavulanic Acid; Drug Resistance, Bacterial; Enzyme Inhibitors; Genetic Variation; Hydrolysis; Isoelectric Focusing; Klebsiella pneumoniae; Microbial Sensitivity Tests; Phenotype; Protein Isoforms; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).
Topics: Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Humans; India; Microbial Sensitivity Tests; Molecular Sequence Data; Prevalence; Pseudomonas aeruginosa; Ribotyping | 2009 |
Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Escherichia coli; Microbial Sensitivity Tests; Molecular Sequence Data; Sequence Homology, Amino Acid | 2009 |
Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; China; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Imipenem; India; Klebsiella; Quinolones; Thailand | 2009 |
Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Klebsiella pneumoniae; Polymerase Chain Reaction | 2009 |
New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
Topics: Anti-Bacterial Agents; beta-Lactamases; Bulgaria; Cefepime; Cefotaxime; Ceftazidime; Cephalosporins; Kinetics; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Sequence Data | 2009 |
Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
Topics: Anti-Bacterial Agents; beta-Lactamases; Blotting, Southern; Carbapenems; China; Electrophoresis, Gel, Pulsed-Field; Enterobacteriaceae; Microbial Sensitivity Tests; Polymerase Chain Reaction | 2009 |
Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
Topics: beta-Lactamases; Computational Biology; Escherichia coli; Models, Genetic; Molecular Sequence Data; Open Reading Frames; Plasmids; United Kingdom | 2009 |
Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; beta-Lactamases; Carboxylic Ester Hydrolases; Cefotaxime; Cefuroxime; Cephalosporins; Cephalothin; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; India; Kinetics; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Sequence Data; Penicillins; Sequence Analysis, DNA; Sequence Homology, Amino Acid | 2009 |
First isolation of the blaOXA-23 carbapenemase gene from an environmental Acinetobacter baumannii isolate.
Topics: Acinetobacter baumannii; beta-Lactamases; DNA, Bacterial; Escherichia coli; France; Genes, Bacterial; Water Microbiology | 2010 |
Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Blotting, Southern; Cloning, Molecular; DNA, Bacterial; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; France; Fresh Water; Gram-Negative Bacteria; Health Surveys; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Pseudomonas fluorescens; Water Microbiology | 2010 |
Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
Topics: Algeria; Anti-Bacterial Agents; Base Sequence; beta-Lactamases; beta-Lactams; Carbapenems; DNA, Bacterial; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Genome, Bacterial; Hospitals, Military; Imipenem; Isoelectric Focusing; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Penicillins; Phenotype | 2010 |
VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Cloning, Molecular; DNA, Bacterial; Escherichia coli; Isoelectric Focusing; Kinetics; Klebsiella pneumoniae; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Mutagenesis, Site-Directed; Plasmids; Protein Conformation; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
Spread of OXA-48-encoding plasmid in Turkey and beyond.
Topics: Anti-Bacterial Agents; Belgium; beta-Lactam Resistance; beta-Lactamases; Carbapenems; DNA Transposable Elements; Egypt; Enterobacteriaceae; Enterobacteriaceae Infections; France; Humans; Lebanon; Microbial Sensitivity Tests; Plasmids; Turkey | 2010 |
PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
Topics: Aeromonas; Animals; Base Sequence; beta-Lactamases; DNA Primers; DNA, Bacterial; Genes, Bacterial; Humans; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Paris; Water Microbiology | 2010 |
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
Topics: Academic Medical Centers; Bacterial Proteins; Base Sequence; beta-Lactamases; Carbapenems; DNA Primers; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Escherichia coli; Escherichia coli Infections; Humans; In Vitro Techniques; Israel; Microbial Sensitivity Tests; Molecular Epidemiology; Plasmids; Time Factors | 2010 |
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
Topics: Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Humans; Israel; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Epidemiology; Phylogeny; Plasmids; Polymerase Chain Reaction | 2010 |
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
Topics: Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cephalosporinase; Clavulanic Acid; Computer Simulation; Enzyme Inhibitors; Hydrogen Bonding; Kinetics; Microbial Sensitivity Tests; Molecular Structure; Mutagenesis, Site-Directed; Penicillanic Acid; Protein Structure, Secondary; Spectrometry, Mass, Electrospray Ionization; Substrate Specificity; Sulbactam; Tazobactam | 2010 |
Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
Topics: Abdomen; Amikacin; beta-Lactams; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Ertapenem; Escherichia coli; Gram-Negative Bacteria; Humans; Imipenem; Microbial Sensitivity Tests | 2010 |
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
Topics: Ampicillin; Ampicillin Resistance; Anti-Bacterial Agents; beta-Lactamases; DNA Mutational Analysis; Enzyme Stability; Escherichia coli; Kinetics; Microbial Sensitivity Tests; Models, Molecular; Protein Conformation; Protein Folding; Structure-Activity Relationship | 2010 |
Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; beta-Lactamases; Child; Child, Preschool; Escherichia coli; Escherichia coli Infections; Female; Humans; Male; Middle Aged; Prospective Studies; Risk Factors; Sweden; Travel; White People; Young Adult | 2010 |
Complete nucleotide sequence of Klebsiella pneumoniae multidrug resistance plasmid pKP048, carrying blaKPC-2, blaDHA-1, qnrB4, and armA.
Topics: Aminoglycosides; Anti-Bacterial Agents; Base Sequence; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Klebsiella pneumoniae; Models, Genetic; Molecular Sequence Data; Plasmids | 2010 |
An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Electrophoresis, Polyacrylamide Gel; Ertapenem; Imipenem; Klebsiella pneumoniae; Meropenem; Molecular Sequence Data; Porins; Thienamycins | 2010 |
Emergence of metallo-β-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia.
Topics: Anti-Bacterial Agents; Australia; beta-Lactamases; beta-Lactams; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Proteins; Methyltransferases; Microbial Sensitivity Tests; Polymerase Chain Reaction | 2010 |
Microbiologic and clinical implications of bacteremia due to extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae with or without plasmid-mediated AmpC beta-lactamase DHA-1.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamases; Carbapenems; Case-Control Studies; Ciprofloxacin; Female; Humans; Klebsiella pneumoniae; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Plasmids; Young Adult | 2010 |
Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
Topics: Amino Acid Sequence; Bacterial Proteins; beta-Lactamases; beta-Lactams; Ertapenem; Meropenem; Microbial Sensitivity Tests; Models, Genetic; Molecular Sequence Data; Open Reading Frames; Pseudomonas aeruginosa; Sequence Homology, Amino Acid; Thienamycins; United States | 2011 |
In vitro activity of ertapenem against common clinical isolates in relation to human pharmacokinetics.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Ceftriaxone; Community-Acquired Infections; Drug Resistance, Microbial; Drug Therapy, Combination; Enterobacteriaceae; Ertapenem; Haemophilus influenzae; Humans; Lactams; Microbial Sensitivity Tests; Moraxella catarrhalis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Staphylococcus aureus; Streptococcus agalactiae; Streptococcus pyogenes | 2002 |
[Investigation of the in-vitro effectiveness of ertapenem against Pseudomonas aeruginosa strains isolated from intensive care unit patients].
Topics: Anti-Bacterial Agents; beta-Lactams; Drug Resistance, Multiple, Bacterial; Ertapenem; Humans; Imipenem; Intensive Care Units; Lactams; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2004 |
Effect of carbapenem administration on establishment of intestinal colonization by vancomycin-resistant enterococci and Klebsiella pneumoniae in mice.
Topics: Animals; beta-Lactams; Carbapenems; Ceftriaxone; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Enterococcus; Ertapenem; Female; Imipenem; Intestines; Klebsiella pneumoniae; Mice; Piperacillin; Sodium Chloride; Time Factors; Vancomycin Resistance | 2007 |
Bactericidal activity of ertapenem against major intra-abdominal pathogens.
Topics: Abdomen; Anti-Bacterial Agents; Bacterial Infections; Bacteroides fragilis; beta-Lactams; Ceftazidime; Ceftriaxone; Digestive System Diseases; Enterobacter cloacae; Enterococcus faecalis; Ertapenem; Escherichia coli; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Klebsiella; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Proteus mirabilis; Staphylococcus aureus; Time Factors | 2006 |
Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Clavulanic Acid; Drug Interactions; Ertapenem; Escherichia coli; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2007 |
Clinical predictors of treatment failure for diabetic foot infections: data from a prospective trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Diabetic Foot; Ertapenem; Female; Humans; Leukocyte Count; Male; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Severity of Illness Index; Treatment Failure | 2007 |
Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infections.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Diabetic Foot; Drug Administration Schedule; Drug Combinations; Ertapenem; Female; Health Care Costs; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2007 |
In vitro activity of piperacillin/tazobactam and ertapenem against Bacteroides fragilis and Escherichia coli in pure and mixed cultures.
Topics: Anti-Bacterial Agents; Bacteroides fragilis; beta-Lactams; Colony Count, Microbial; Ertapenem; Escherichia coli; Microbial Sensitivity Tests; Microbial Viability; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Time Factors | 2007 |
Comparative activity of ertapenem and piperacillin tazobactam in a murine systemic infection model with Bacteroides fragilis and Escherichia coli.
Topics: Animals; Anti-Bacterial Agents; Ascitic Fluid; Bacteroides fragilis; Bacteroides Infections; beta-Lactams; Blood; Colony Count, Microbial; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Mice; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis | 2007 |
Killing of Escherichia coli by beta-lactams at different inocula.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Ceftriaxone; Colony Count, Microbial; Ertapenem; Escherichia coli; Humans; Microbial Viability; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Time Factors | 2009 |
Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Cost-Benefit Analysis; Decision Trees; Diabetic Foot; Direct Service Costs; Drug Costs; Drug Resistance, Bacterial; Ertapenem; Humans; Models, Biological; Models, Econometric; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Quality-Adjusted Life Years; Treatment Outcome; United Kingdom | 2009 |
In vitro selection of ertapenem and piperacillin/tazobactam-resistant strains of Bacteroides fragilis and analysis of their virulence in gnotobiotic mice.
Topics: Animals; Anti-Bacterial Agents; Bacteroides fragilis; Bacteroides Infections; beta-Lactam Resistance; beta-Lactams; Ertapenem; Germ-Free Life; In Vitro Techniques; Mice; Microbial Sensitivity Tests; Penicillanic Acid; Phenotype; Piperacillin; Tazobactam; Virulence | 2010 |
Superior in vitro activity of ertapenem and piperacillin/tazobactam against recent clinical isolates of Proteus mirabilis from intra-abdominal infections (SMART 2009-2010).
Topics: Abdominal Abscess; Anti-Bacterial Agents; beta-Lactams; Ertapenem; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Proteus Infections; Proteus mirabilis | 2011 |
Effect of body mass index on treatment of complicated intra-abdominal infections in hospitalized adults: comparison of ertapenem with piperacillin-tazobactam.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Body Mass Index; Ertapenem; Female; Humans; Intraabdominal Infections; Male; Middle Aged; Multicenter Studies as Topic; Obesity, Morbid; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Randomized Controlled Trials as Topic; Young Adult | 2012 |
Broad-spectrum β-lactam antibiotics for treating experimental peritonitis in mice due to Klebsiella pneumoniae producing the carbapenemase OXA-48.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Cefotaxime; Ceftazidime; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Ertapenem; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Lethal Dose 50; Mice; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Plasmids; Survival Rate | 2012 |
Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART).
Topics: Amikacin; Anti-Bacterial Agents; Asia; Australasia; beta-Lactamases; beta-Lactams; Carbapenems; Ceftazidime; Drug Resistance, Bacterial; Ertapenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prevalence; Prospective Studies; Urinary Tract Infections | 2012 |
Susceptibility to antibiotics of aerobic bacteria isolated from community acquired secondary peritonitis in children: therapeutic guidelines might not always fit with and everyday experience.
Topics: Ampicillin; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Child; Community-Acquired Infections; Drug Resistance, Bacterial; Drug Therapy, Combination; Ertapenem; Gentamicins; Hospitals, Pediatric; Humans; Italy; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Guidelines as Topic; Sulbactam; Thienamycins | 2013 |
Impact of a Dynamic Microbiological Environment on the Clinical Efficacy of Ertapenem and Piperacillin/Tazobactam in the Treatment of Complicated Community-Acquired Intra-Abdominal Infection in Spain: A Cost-Consequence Analysis.
Topics: Anti-Bacterial Agents; APACHE; beta-Lactams; Clinical Trials, Phase III as Topic; Community-Acquired Infections; Cost-Benefit Analysis; Decision Trees; Double-Blind Method; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Ertapenem; Humans; Intraabdominal Infections; Length of Stay; Models, Economic; Monte Carlo Method; Multicenter Studies as Topic; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Spain | 2015 |
Antimicrobial Susceptibilities of Aerobic and Facultative Gram-Negative Bacilli from Intra-abdominal Infections in Patients from Seven Regions in China in 2012 and 2013.
Topics: Amikacin; Ampicillin; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cefoxitin; China; Ciprofloxacin; Community-Acquired Infections; Cross Infection; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Gene Expression; Humans; Imipenem; Intraabdominal Infections; Levofloxacin; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam | 2016 |
Antimicrobial susceptibility of clinical Enterobacteriaceae isolates at the emergency department in a regional hospital: A threat of extended spectrum beta-lactamase-producers among nursing home residents.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Blood; Drug Resistance, Multiple, Bacterial; Emergency Service, Hospital; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Microbial Sensitivity Tests; Nursing Homes; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Proteus Infections; Proteus mirabilis; Retrospective Studies; Sputum; Taiwan; Thienamycins; Urine | 2016 |
An Immunocompromised Child with Bloodstream Infection Caused by Two Escherichia coli Strains, One Harboring NDM-5 and the Other Harboring OXA-48-Like Carbapenemase.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactamases; beta-Lactams; Ciprofloxacin; Ertapenem; Escherichia coli; Female; Gentamicins; Humans; Immunocompromised Host; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam; Thienamycins; Tobramycin | 2016 |
IMP-27, a Unique Metallo-β-Lactamase Identified in Geographically Distinct Isolates of Proteus mirabilis.
Topics: Aztreonam; beta-Lactamases; beta-Lactams; Ceftazidime; Drug Resistance, Bacterial; Ertapenem; Hydrolysis; Integrons; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Proteus Infections; Proteus mirabilis; United States | 2016 |
Bypass graft infection and bacteremia caused by Anaerostipes caccae: First report of human infection caused by a recently described gut anaerobe.
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Anastomosis, Surgical; Anti-Bacterial Agents; beta-Lactams; Blood Culture; Clostridiales; Ertapenem; Female; Gram-Positive Bacterial Infections; Humans; Metronidazole; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Surgical Wound Infection; Vancomycin | 2016 |
Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013-2015.
Topics: Acinetobacter baumannii; Amikacin; Anti-Infective Agents; Asia; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacter; Ertapenem; Gram-Negative Bacteria; Hospitalization; Humans; Imipenem; Intraabdominal Infections; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Urinary Tract Infections | 2017 |
Treatment efficacy and superinfection rates in complicated urinarytract infections treated with ertapenem or piperacillin tazobactam.
Topics: Anti-Bacterial Agents; beta-Lactams; Ertapenem; Humans; Penicillanic Acid; Piperacillin; Retrospective Studies; Superinfection; Tazobactam; Treatment Outcome | 2016 |
Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Hospitals, University; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pyelonephritis; Republic of Korea; Retrospective Studies; Survival Analysis; Treatment Failure; Young Adult | 2017 |
Carbapenemase-Producing Enterobacteriaceae Isolates from Edo State, Nigeria.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenem-Resistant Enterobacteriaceae; Cefotaxime; Ceftazidime; Disk Diffusion Antimicrobial Tests; Enterobacteriaceae Infections; Ertapenem; Fluoroquinolones; Humans; Nigeria; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2017 |
Evaluation of First-Dose, Intravenous Push Penicillins and Carbapenems in the Emergency Department.
Topics: Ampicillin; Anti-Bacterial Agents; Carbapenems; Emergency Service, Hospital; Ertapenem; Humans; Penicillins; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Sulbactam | 2022 |